MONROVIA, Calif., May 9, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today reported financial results for the first quarter ended March 31, 2017 and provided a review of business and clinical highlights. 'We have been focused on advancing our clinical development pipeline across the breadth of our portfolio,' said Bassil Dahiyat, Ph.D., president and chief executive officer of Xencor. 'Today, we are pleased to announce data from our Phase 1 trial of subcutaneously administered XmAb5871, which support use of this...
↧